A detailed history of Woodline Partners LP transactions in Catalent, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 581,346 shares of CTLT stock, worth $36.9 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
581,346
Previous 588,833 1.27%
Holding current value
$36.9 Million
Previous $33.1 Million 6.35%
% of portfolio
0.32%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$56.16 - $60.96 $420,469 - $456,407
-7,487 Reduced 1.27%
581,346 $35.2 Million
Q2 2024

Aug 14, 2024

SELL
$53.58 - $57.02 $6.74 Million - $7.17 Million
-125,752 Reduced 17.6%
588,833 $33.1 Million
Q1 2024

May 15, 2024

BUY
$42.56 - $59.82 $30.4 Million - $42.7 Million
714,585 New
714,585 $40.3 Million
Q1 2023

May 15, 2023

BUY
$45.44 - $74.26 $320,533 - $523,830
7,054 New
7,054 $463,000
Q2 2022

Aug 15, 2022

BUY
$87.2 - $114.05 $685,653 - $896,775
7,863 New
7,863 $844,000
Q4 2021

Feb 14, 2022

SELL
$119.57 - $139.07 $11 Million - $12.8 Million
-91,807 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$109.17 - $142.35 $6.17 Million - $8.04 Million
56,480 Added 159.88%
91,807 $12.2 Million
Q2 2021

Aug 16, 2021

BUY
$100.34 - $115.69 $3.54 Million - $4.09 Million
35,327 New
35,327 $3.82 Million
Q3 2020

Nov 16, 2020

SELL
$72.74 - $92.5 $4.72 Million - $6 Million
-64,880 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$48.02 - $79.04 $3.12 Million - $5.13 Million
64,880 New
64,880 $4.76 Million
Q1 2020

May 15, 2020

SELL
$36.95 - $62.95 $15.2 Million - $25.9 Million
-410,986 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$47.06 - $56.64 $19.3 Million - $23.3 Million
410,986 New
410,986 $23.1 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.